Drug intelligence / Profile preview

CGG101

Development stage
Preclinical
Lead developer
Cure Genetics
Modality
Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

CGG101 is an investigational gene therapy being developed by Suzhou Cure Genetics (CureGenetics) for the treatment of cardiovascular diseases. The program utilizes the company's proprietary Virus-like Exosome-Like Particle (VELP) delivery platform, which is a hybrid system designed to combine the high transduction efficiency of viral vectors with the low immunogenicity and biocompatibility of exosomes. This approach aims to facilitate targeted delivery of genetic payloads to cardiovascular tissues while minimizing off-target effects and immune-mediated clearance. Currently in the preclinical stage, CGG101 represents an application of CureGenetics' delivery technology to address unmet needs in cardiovascular medicine.

Beyond the preview

Go deeper on CGG101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CGG101.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call